CR10289A - "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional) - Google Patents

"estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)

Info

Publication number
CR10289A
CR10289A CR10289A CR10289A CR10289A CR 10289 A CR10289 A CR 10289A CR 10289 A CR10289 A CR 10289A CR 10289 A CR10289 A CR 10289A CR 10289 A CR10289 A CR 10289A
Authority
CR
Costa Rica
Prior art keywords
stratriens
strogens
alfa
divisional
substituted
Prior art date
Application number
CR10289A
Other languages
English (en)
Inventor
Diek Kosemund
Gerd Muller
Alexander Hillisch
Karl-Heinrich Fritzemeier
Peter Muhn
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR10289A publication Critical patent/CR10289A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a nuevos compuestos como ingredientes activos farmaceuticos que presentan in vitro una mayor afinidad en preparaciones de receptores de estrogeno de prostata de rata que en preparaciones de receptores de estrogeno de utero de rata y que presentan in vivo un efecto preferencial en el ovario en comparacion con el utero, a su preparacion, a su aplicacion terapeutica y a formas farmaceuticas que contienen los nuevos compuestos.
CR10289A 2002-06-11 2008-09-16 "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional) CR10289A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Publications (1)

Publication Number Publication Date
CR10289A true CR10289A (es) 2008-11-26

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10289A CR10289A (es) 2002-06-11 2008-09-16 "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)

Country Status (29)

Country Link
EP (1) EP1517914B1 (es)
JP (1) JP4615998B2 (es)
KR (1) KR101006612B1 (es)
CN (1) CN1293090C (es)
AR (1) AR040188A1 (es)
AT (1) ATE303397T1 (es)
AU (1) AU2003242683B9 (es)
BR (1) BR0312140A (es)
CA (1) CA2486495C (es)
CR (1) CR10289A (es)
CU (1) CU23414B7 (es)
DE (2) DE10226326A1 (es)
DK (1) DK1517914T3 (es)
EA (1) EA008442B1 (es)
EC (1) ECSP055530A (es)
ES (1) ES2248770T3 (es)
HK (1) HK1081203A1 (es)
HR (1) HRP20050009B1 (es)
IL (1) IL165321A (es)
MX (1) MXPA04012491A (es)
NO (1) NO329563B1 (es)
PE (1) PE20040613A1 (es)
PL (1) PL209910B1 (es)
RS (1) RS50878B (es)
TW (1) TWI286140B (es)
UA (1) UA78062C2 (es)
UY (1) UY27844A1 (es)
WO (1) WO2003104253A2 (es)
ZA (1) ZA200500217B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE602004014020D1 (de) * 2003-11-26 2008-07-03 Bayer Schering Pharma Ag Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
BRPI0908231A2 (pt) * 2008-02-13 2015-07-21 Bayer Schering Pharma Akltiengesellschaft Sistema de liberação de fármaco com efeito estabilizante
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
EP2358351A1 (en) * 2008-11-21 2011-08-24 Bayer Pharma Aktiengesellschaft Drug delivery system
US10821152B2 (en) 2014-08-26 2020-11-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
DE50014299D1 (de) * 1999-11-02 2007-06-14 Bayer Schering Pharma Ag 18-nor-steroide als selektiv wirksame estrogene
EP1272505B1 (de) * 2000-04-12 2005-08-24 Schering Aktiengesellschaft 8beta-substituierte-11beta-pentyl-und 11beta-hexyl-estra-1,3,5(10)-trienderivate

Also Published As

Publication number Publication date
CN1293090C (zh) 2007-01-03
JP4615998B2 (ja) 2011-01-19
CN1659181A (zh) 2005-08-24
RS50878B (sr) 2010-08-31
KR20050009745A (ko) 2005-01-25
NO329563B1 (no) 2010-11-15
TWI286140B (en) 2007-09-01
EA008442B1 (ru) 2007-06-29
NO20050127L (no) 2005-03-11
MXPA04012491A (es) 2005-06-08
AU2003242683A1 (en) 2003-12-22
UA78062C2 (en) 2007-02-15
HRP20050009A2 (en) 2005-04-30
ATE303397T1 (de) 2005-09-15
DE10226326A1 (de) 2004-01-15
JP2005533053A (ja) 2005-11-04
CU23414B7 (es) 2009-09-08
AR040188A1 (es) 2005-03-16
WO2003104253A3 (de) 2004-09-16
EP1517914A2 (de) 2005-03-30
ECSP055530A (es) 2005-03-10
RS107004A (en) 2006-10-27
ZA200500217B (en) 2006-03-29
EP1517914B1 (de) 2005-08-31
KR101006612B1 (ko) 2011-01-10
CA2486495C (en) 2011-04-19
ES2248770T3 (es) 2006-03-16
HK1081203A1 (en) 2006-05-12
PL373090A1 (en) 2005-08-08
NO20050127D0 (no) 2005-01-10
BR0312140A (pt) 2005-04-05
HRP20050009B1 (hr) 2013-07-31
IL165321A (en) 2009-08-03
DE50301116D1 (de) 2005-10-06
WO2003104253A2 (de) 2003-12-18
UY27844A1 (es) 2003-12-31
PL209910B1 (pl) 2011-11-30
CA2486495A1 (en) 2003-12-18
AU2003242683B9 (en) 2009-08-27
PE20040613A1 (es) 2004-12-01
DK1517914T3 (da) 2006-01-16
AU2003242683B2 (en) 2009-07-02
EA200401544A1 (ru) 2005-06-30
TW200407331A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
CR7022A (es) Productos esteroides hormonales y metodos para su preparacion
EA200201000A1 (ru) Гормон-заместительная терапия
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
PT971705E (pt) Formulacoes de farmacos de terapeutica de substituicao hormonal para aplicacao topica na pele
WO2002017918A3 (en) Sustained release formulations for growth hormone secretagogues
DK1299108T3 (da) Parasiticidt præparat samt fremgangsmåde til fremstilling af dette præparat
HN1999000124A (es) Derivados de pirazol substituido.
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
ES2185124T3 (es) Composiciones de teñido de las fibras queratinicas que contienen derivados de indazoles de amina y procedimiento de teñido.
SG152257A1 (en) Topical preparation containing ambroxol
GT199900203A (es) Composiciones de celecoxib.
HK1080364B (zh) 具有改進的生物利用率的液體藥物口服藥物劑型
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
BR0208163A (pt) Terapia de reposição hormonal
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
BR0310085A (pt) Terapia de substituição de hormÈnio
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
BR0311184A (pt) Terapia de reposição de hormÈnio
AR039228A1 (es) Terapia de reemplazo hormonal
WO2004014318A3 (en) Levothyroxine compositions and methods

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)